Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded down 13.9% during mid-day trading on Wednesday . The company traded as low as C$0.14 and last traded at C$0.16. 295,053 shares traded hands during trading, a decline of 43% from the average session volume of 519,469 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$25.50 million, a price-to-earnings ratio of -5.10 and a beta of 0.20. The stock has a 50-day moving average of C$0.20 and a two-hundred day moving average of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Invest in Blue Chip Stocks
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Best Stocks Under $10.00
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
